The chemotherapy regimen known as FOLFIRINOX produces an "impressive clinical response" in locally advanced pancreatic ductal adenocarcinoma, according to the authors of a new small, retrospective, ...

Please provide your email address to receive an email when new articles are posted on . The addition of modified FOLFIRINOX induction chemotherapy to standard care improved metastasis-free survival.

Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a ...

(RTTNews) - Immuneering Corporation (IMRX), a Massachusetts-based biopharmaceutical company Monday announced a positive update from its Phase 2a study of IMM-1-104 combined with modified FOLFIRINOX ...

More than 30% of patients with pancreatic cancer are unresectable because of the local extension with a median overall survival (OS) of <1 year. Combination of fluorouracil (FU), oxaliplatin, and ...

Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine + ...

The authors evaluated the efficacy of a doublet regimen of gemcitabine with nab-paclitaxel in the treatment of advanced pancreatic cancer in the first-line setting. A total of 861 patients in this ...

CHICAGO -- A neoadjuvant chemotherapy regimen of cisplatin (Platinol), nab-paclitaxel (Abraxane), capecitabine (Xeloda), and gemcitabine (PAXG) topped a standard option in a randomized trial of ...

New Haven, Conn. — Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by ...